SCHEMBL18987115

SCHEMBL18987115

CCCCCCc1cc(CCCCCC)cc(C2(C)c3ccccc3-c3ccc(-c4ncc(B5OC(C)(C)C(C)(C)O5)c5ccccc45)cc32)c1

nearest known ligand 0.37

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
LPL P06858 5/20 0.37
LIPG Q9Y5X9 5/20 0.37
HSD11B1 P28845 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19001626 0.95 LPL (0.35) LPLLIPGHSD11B1
SCHEMBL18987035 0.84 HSD11B1 (0.33) HSD11B1
SCHEMBL20623312 0.83
SCHEMBL18216926 0.82 DGAT1 (0.46) LPLLIPGHSD11B1
SCHEMBL19001597 0.80 HSD11B1 (0.33) HSD11B1
SCHEMBL18216925 0.79 LIPG (0.54) LPLLIPGHSD11B1
SCHEMBL19001624 0.74 ADORA3 (0.31)
SCHEMBL19001622 0.74 LIPG (0.50) LPLLIPGHSD11B1
SCHEMBL18216924 0.74 RAB9A (0.44) HSD11B1
SCHEMBL46866 0.74 LIPG (0.60) LPLLIPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11214585-B2 Light-emitting composition CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2022-01-04 US disclosed
EP-3390418-B1 LIGHT-EMITTING COMPOUND CAMBRIDGE DISPLAY TECH LTD (GB) 2020-08-05 EP disclosed
US-20190002629-A1 LIGHT-EMITTING COMPOSITION CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2019-01-03 US disclosed
US-20190002488-A1 LIGHT-EMITTING COMPOUND CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2019-01-03 US disclosed
EP-3390419-A1 LIGHT-EMITTING COMPOSITION Cambridge Display Technology Limited (GB) 2018-10-24 EP disclosed
EP-3390418-A1 LIGHT-EMITTING COMPOUND Cambridge Display Technology Limited (GB) 2018-10-24 EP disclosed
WO-2017103584-A1 LIGHT-EMITTING COMPOUND CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2017-06-22 WO disclosed
WO-2017103584-A1 LIGHT-EMITTING COMPOUND CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2017-06-22 WO disclosed
WO-2017103586-A1 LIGHT-EMITTING COMPOSITION CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2017-06-22 WO disclosed
WO-2017103586-A1 LIGHT-EMITTING COMPOSITION CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2017-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11214585-B2 Light-emitting composition CRY1, CRY2, ARL1 LPL 3129/4885LIPG 4565/4885HSD11B1 1840/4885
US-20190002488-A1 LIGHT-EMITTING COMPOUND AR, ARL1, IK LPL 4248/4885LIPG 4713/4885HSD11B1 927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.